NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
NEWS Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG ByOncoscience 22. July 201517. July 2025
NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 202217. July 2025
NEWS Oncoscience AG established scientific advisory board ByOncoscience 15. October 200417. July 2025
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
